Arizona State Retirement System Sells 243 Shares of Enovis Co. (NYSE:ENOV)

Arizona State Retirement System decreased its stake in shares of Enovis Co. (NYSE:ENOV) by 1.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,722 shares of the company’s stock after selling 243 shares during the period. Arizona State Retirement System’s holdings in Enovis were worth $769,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of ENOV. UMB Bank n.a. bought a new stake in shares of Enovis during the 3rd quarter valued at about $31,000. Fifth Third Bancorp boosted its stake in Enovis by 144.6% during the third quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock worth $31,000 after acquiring an additional 347 shares in the last quarter. State of Wyoming boosted its stake in Enovis by 59,200.0% during the fourth quarter. State of Wyoming now owns 593 shares of the company’s stock worth $32,000 after acquiring an additional 592 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in Enovis by 902.7% during the third quarter. First Horizon Advisors Inc. now owns 732 shares of the company’s stock worth $39,000 after acquiring an additional 659 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Enovis during the fourth quarter worth about $63,000. Institutional investors own 98.45% of the company’s stock.

Enovis Trading Down 0.5 %

Shares of NYSE ENOV opened at $56.24 on Thursday. The firm’s 50 day moving average price is $60.49 and its 200-day moving average price is $55.29. The company has a market cap of $3.08 billion, a PE ratio of -92.20 and a beta of 1.97. Enovis Co. has a 52-week low of $43.04 and a 52-week high of $66.14. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.16 and a current ratio of 2.43.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 22nd. The company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.03. Enovis had a negative net margin of 1.95% and a positive return on equity of 3.84%. The firm had revenue of $455.00 million during the quarter, compared to analysts’ expectations of $444.34 million. During the same period in the previous year, the company earned $0.72 earnings per share. The firm’s quarterly revenue was up 11.2% on a year-over-year basis. On average, equities research analysts expect that Enovis Co. will post 2.58 EPS for the current fiscal year.

Analyst Ratings Changes

ENOV has been the topic of several research reports. UBS Group initiated coverage on shares of Enovis in a research note on Monday, January 22nd. They set a “buy” rating and a $75.00 price objective on the stock. William Blair initiated coverage on shares of Enovis in a research note on Wednesday, January 3rd. They set an “outperform” rating on the stock. Stephens initiated coverage on shares of Enovis in a research note on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on shares of Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $82.00 target price on shares of Enovis in a research note on Wednesday, April 10th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $75.43.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.